Stockscreener 앱 받기
2.64
4.35%
-0.12
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
JPMorgan reports ownership above 5% in Lexeo Therapeutics (LXEO). - Stock Titan
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
A healthcare conference fireside chat will stream live Oct. 20, featuring Lexeo Therapeutics. - Stock Titan
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17 - Investing.com
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) - GlobeNewswire Inc.
Lexeo Therapeutics Finalizes Acquisition of Mantle Therapeutics in $8.3M Cash and Stock Deal - Kalkine Media
Form 8K Lexeo Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Lexeo Therapeutics completes acquisition of Mantle Therapeutics - Investing.com
Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger - TipRanks
Lexeo Therapeutics completes acquisition of Mantle Therapeutics By Investing.com - Investing.com South Africa
Lexeo Therapeutics completes acquisition of Mantle Therapeutics By Investing.com - Investing.com India
Form 8K Lexeo Therapeutics Inc For: 29 September By Investing.com - Investing.com Canada
Lexeo Therapeutics (LXEO) medical chief acquires 2,714 shares through an employee plan - Stock Titan
Lexeo Therapeutics (LXEO) awards its COO an option covering 54,750 shares - Stock Titan
At $3.39 a share, Lexeo Therapeutics (LXEO) grants its CFO 54,750 stock options. - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,306 shares through an employee plan and receives a stock option. - Stock Titan
A virtual heart-and-metabolism forum will include Lexeo on Sept. 30. - Stock Titan
Why is Lexeo Therapeutics stock gaining today? - Investing.com
Lexeo Therapeutics to Acquire Mantle Therapeutics for $8.3M Upfront, Up to $13M in Milestones - TradingView
Lexeo Therapeutics (NasdaqGM:LXEO) Stock Forecast & Analyst Predictions - Simply Wall Street
Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million . - marketscreener.com
We're Not Very Worried About Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Rate - simplywall.st
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Nigeria
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Canada
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - The Manila Times
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - Yahoo Finance
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan
Lexeo (NASDAQ: LXEO) holder plans stock sale to cover tax bill - Stock Titan
Lexeo Therapeutics (LXEO) holder plans 1,304-share sale - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
META_TITLE_QUOTE - Yahoo Finance
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks
4.22%
자본화:
|
볼륨(24시간):